TITLE

EVOTEC OAI/PANACOS TO DEVELOP ANTI-HIV THERAPIES

PUB. DATE
May 2004
SOURCE
Worldwide Biotech;May2004, Vol. 16 Issue 5, p7
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Focuses on the medicinal chemistry collaboration between Evotec OAI AG and Panacos Pharmaceuticals Inc. Information on Panacos' clinical trials on PA-457 HIV drug; Business strategy of Evotec; Proprietary discovery technologies of Panacos.
ACCESSION #
13040777

 

Related Articles

  • Panacos Sheds 62% On Latest Phase IIb Data For Bevirimat. Morris, Trista // BioWorld Today;12/12/2007, Vol. 18 Issue 240, p1 

    The article reports that the preliminary data from Panacos Pharmaceuticals Inc.'s latest Phase IIb trial with HIV drug bevirimat have caused the company's shares to fall 61.7 percent. The data indicated a lower mean viral load reduction and fewer responders with the 350-milligram solution of...

  • Evotec uses collaborations to supplement pipeline.  // PharmaWatch: CNS;May 2004, Vol. 3 Issue 5, p6 

    Reports on the collaboration of Evotec OAI AG and Panacos Pharmaceuticals Inc. to develop and market a patent portfolio. Design and optimization of novel anti-HIV compounds; Initiation of a phase I clinical trials of Panacos' small molecule intended to treat HIV infection; Efficacy of the drug...

  • Panacos: developing the antiretroviral armory.  // PharmaWatch: Monthly Review;Oct2005, Vol. 4 Issue 10, p34 

    The article reports that Phase IIa data published by Panacos Pharmaceuticals Inc. has revealed that the company's lead HIV compound, PA-457, met the trial's primary endpoint. As such, the maturation inhibitor has moved a step closer to being able to provide a new option for patients resistant to...

  • MARYLAND: Penacos Pharma gets fast-track status for HIV drug.  // Gay & Lesbian Times;1/20/2005, Issue 891, p30 

    Reports that Panacos Pharmaceuticals Inc. has received fast-track status from the U.S. Food and Drug Administration for PA, 457, the company's oral drug candidate for HIV. Aim of the fast-track status to expedite development and approval of new drugs that may have the potential to improve...

  • New hope in the fight against HIV/AIDS.  // Contemporary Sexuality;Nov2005, Vol. 39 Issue 11, p10 

    The article reports that Panacos Pharmaceuticals Inc. is in the process of developing PA-457, a drug which will reduce the level of HIV in those who are suffering from AIDS. Panacos is a U.S. firm based in Watertown, Massachusetts. PA-457 works by a mechanism different from that of approved...

  • Bevirimat Data Help Locate Responders.  // Bioworld Week;3/10/2008, Vol. 16 Issue 10, p4 

    The article investigates on the beneficial use of the human immunodeficiency virus (HIV) maturation inhibitor bevirimat from Panacos Pharmaceuticals Inc. in predicting the responses among HIV patients in Watertown, Massachusetts. Results of Phase IIb trial show that patients whose virus has...

  • Panacos Sheds 62% On Bevirimat Phase IIb Data.  // Bioworld Week;12/17/2007, Vol. 15 Issue 51, p4 

    The article reports on the decline in the stock prices of Panacos Pharmaceuticals Inc. by 61.7 percent due to preliminary data from the latest cohort of a Phase IIb trial with HIV drug bevirimat in the U.S. The data indicated a lower mean viral load reduction and fewer responders with the 350-mg...

  • Panacos HIV Drug Gets Fast-Track Status from FDA.  // Clinical Infectious Diseases;3/1/2005, Vol. 40 Issue 5, preceding p1 

    The article reports that Panacos Pharmaceuticals Inc., which is to merge shortly with V.I. Technologies Inc., said that the U.S. regulators will review its experimental drug to combat HIV on an accelerated basis. The drug, PA-457, is currently in middle stage, or phase II, clinical trials and is...

  • FINE CHEMICALS. Tyler, Alan // European Chemical News;7/26/2004, Vol. 81 Issue 2110, p23 

    Presents news briefs on the chemical industry as of July 26, 2004. Acquisition of Pfizer's manufacturing complex in Mexico City, Mexico by U.S. pharmaceutical firm Ivax; Partnership between Germany's Evotec OAI and U.S. biotech firm Biogen Idec; Sale of Organon's pharmaceuticals plant in Buenos...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics